These innovative molecules represent a significant progression in the therapy of type 2 diabetes. Retatrutide, a triple GLP-1 and GIP receptor agonist, demonstrates promising efficacy in lowering blood glucose levels. https://aoifewcdn358700.creacionblog.com/38999536/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide